Skin rash occurs most commonly with the NNRTI class of drugs. Most cases are mild to moderate in nature, occurring within the first few weeks of therapy. Some experts suggest managing skin rash with antihistamines for symptomatic relief without drug discontinuation, although the wisdom of treating through such rashes has been questioned [188]. More serious cutaneous manifestations such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) should result in the prompt and permanent discontinuation of NNRTIs or other offending agents.